#Biotech Stock News: Positive
Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V)
(OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)
Point Roberts, WA,
Delta BC - March 27, 2019 - Investorideas.com, a leading investor news resource covering
biotech and pharma stocks releases a snapshot looking at the biopharmaceutical
market and how monoclonal antibody research is gaining market dominance.
GELifesciences.com,
talking about the Antibody boom says; “Many small
and start-up companies are developing new ideas as to how antibodies can be
used. In many cases, these companies will go on to be acquired by larger
companies with the financial capability to progress their ideas further. But
with costs to establish manufacturing capability in suitable existing buildings
at not much more than $10-15 M, this strategic opportunity lies within reach
even for smaller businesses. Despite steep competition and the need for
significant investment, the antibody space is a lucrative opportunity with
various therapeutic avenues that can be explored.”
Looking at some companies in the sector, Immunoprecise Antibodies Ltd. (TSXV: IPA) (OTC: IPATF), a therapeutic antibody discovery
company, recently received a five-year
Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos
Biomedical Research, Inc., which currently operates the Frederick National
Laboratory for Cancer Research for the National Cancer Institute (NCI). Under
the subcontract, IPA will discover and produce rabbit monoclonal antibodies
using its proprietary B-Cell Select platform.
The rabbit monoclonal antibodies discovered and produced
under this subcontract will be used in the key applications of
immunohistochemistry and immuno-Multiple Reaction Monitoring (immuno-MRM). The
antibodies will be generated for NCI’s Antibody Characterization Program.
Immuno-MRM is a leading-edge targeted mass spectrometry
technique that relies on antibodies to enrich peptides from complex biological
samples that are then quantified by mass spectrometry. Rabbit monoclonal
antibodies are highly sought after for this purpose because they exhibit high
specificity and bind their target with high affinity. Immuno-MRM is being used
to discover novel biomarkers and develop a new generation of clinical
diagnostic tests that could lead to improved cancer detection, diagnosis, and
treatment.
Zymeworks
Inc. (NYSE: ZYME) (TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional therapeutics reported in January the
achievement of a new development milestone in its collaboration with Eli Lilly
and Company. In accordance with Zymeworks’ 2014 licensing and collaboration
agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0
million for Lilly’s submission of an IND application for an immuno-oncology
bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform.
Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company
advancing targeted fusion protein therapeutics for the treatment of cancer
recently reported positive preliminary efficacy data
for the primary endpoint of its ongoing Phase 3 registration trial, the VISTA
Trial, of Vicinium® for the treatment of patients with high-grade
non-muscle invasive bladder cancer (NMIBC) who have been previously treated
with bacillus Calmette-Guérin (BCG) and deemed BCG-unresponsive. The data
reported show clinically meaningful complete response rates in evaluable
Carcinoma in situ patients at three,
six, nine and twelve months of follow-up in the trial consistent with the data
in the completed Phase 1 and Phase 2 clinical trials. Importantly, Vicinium
continues to be generally well-tolerated in treated patients.
ProMIS Neurosciences, Inc. (TSX: PMN) (OTC: ARFXF), a biotechnology company focused
on the discovery and development of antibody therapeutics targeting toxic
oligomers implicated in the development of neurodegenerative diseases will soon present data for new
antibody candidates that show stringent selectivity for the toxic forms of
alpha-synuclein, considered a root cause of Parkinson's disease. ProMIS Neurosciences' Chief Scientific
Officer, Dr. Neil Cashman will discuss the preclinical data at a podium
presentation on March 31 as well as co-moderate the March 30 panel discussion
on disease mechanisms in Alzheimer's disease and Parkinson's disease.
ResearchandMarkets, in a biopharma
market overview reported, “The global biopharmaceuticals market was valued at
USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3
million in 2024, witnessing a CAGR of 8.59%.”
Within the related
segments, Monoclonal Antibodies are expected to gain the largest market size.
For investors
following medical technology and healthcare stocks, Investor Ideas has created a directory of biotech and medical
technology stocks
About Investorideas.com - News that Inspires
Big Investing Ideas
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos
talking about cannabis,
crypto, technology including AI and IoT , mining ,sports biotech, water,
renewable energy and more . Investorideas.com original branded content includes
the daily Crypto
Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI
Follow us on Social Media
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this
news article featuring (TSX VENTURE: IPA)
(OTC PINK: IPATF) a paid for service on Investorideas.com(third
party) . Learn more about costs and our services
https://www.investorideas.com/News-Upload/
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Contact Investorideas.com
800-665-0411
